Galapagos announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its board of directors has given the green light.
In October 2025, the Belgium-based biotech revealed its intention to discontinue its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. The decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed.
The wind down will impact approximately 365 employees across Europe, the U.S. and China, as well as the closure of the sites in Leiden (the Netherlands), Basel (Switzerland), Princeton and Pittsburgh (U.S.), and Shanghai (China). The remaining Galapagos org will keep a dedicated presence at its headquarters in Mechelen, Belgium.
The non-cell therapy activities, including the TYK2 program GLPG3667, will continue to be managed by Galapagos.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!